Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: A phase II trial of temsirolimus in second-line metastatic urothelial cancer.
Journal: Medical oncology (Northwood, London, England) 20121201
Title: Phase II trial of temsirolimus in patients with metastatic breast cancer.
Journal: Breast cancer research and treatment 20121101
Title: Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.
Journal: Cancer 20121015
Title: Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20121015
Title: Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
Journal: Investigational new drugs 20121001
Title: Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
Journal: International journal of urology : official journal of the Japanese Urological Association 20121001
Title: Novel agents in Hodgkin lymphoma.
Journal: Current oncology reports 20121001
Title: Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120920
Title: Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Journal: International journal of pharmaceutics 20120915
Title: Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?
Journal: Anti-cancer drugs 20120901
Title: Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology 20120901
Title: Temsirolimus: a safety and efficacy review.
Journal: Expert opinion on drug safety 20120901
Title: Inhibition of mTOR in carcinoid tumors.
Journal: Targeted oncology 20120901
Title: Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
Journal: Acta oncologica (Stockholm, Sweden) 20120901
Title: Emerging agents for the treatment of mantle cell lymphoma.
Journal: Expert review of anticancer therapy 20120901
Title: Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Journal: The oncologist 20120801
Title: Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus.
Journal: Anticancer research 20120801
Title: Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Journal: Neoplasia (New York, N.Y.) 20120801
Title: Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation.
Journal: Science translational medicine 20120725
Title: Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery.
Journal: Advanced materials (Deerfield Beach, Fla.) 20120717
Title: Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.
Journal: The Journal of biological chemistry 20120706
Title: Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
Journal: European journal of cancer (Oxford, England : 1990) 20120701
Title: A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
Journal: Cancer chemotherapy and pharmacology 20120701
Title: Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.
Journal: Medical oncology (Northwood, London, England) 20120601
Title: Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120601
Title: Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Journal: Clinical and experimental nephrology 20120601
Title: Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus).
Journal: DNA and cell biology 20120601
Title: Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Journal: Journal of cancer research and clinical oncology 20120601
Title: A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.
Journal: Cancer chemotherapy and pharmacology 20120601
Title: The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
Journal: Endocrine-related cancer 20120601
Title: Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120601
Title: Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120601
Title: Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20120601
Title: [Renal carcinoma: point on treatment of brain metastasis].
Journal: Bulletin du cancer 20120601
Title: Molecular characterization and functional analysis of Cashmere goat mammalian target of rapamycin.
Journal: DNA and cell biology 20120501
Title: Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Journal: Biochemical pharmacology 20120501
Title: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120501
Title: Stability of ready-to-use temsirolimus infusion solution (100mg/L) in polypropylene containers under different storage conditions.
Journal: Annales pharmaceutiques francaises 20120501
Title: Brief report: a phase II 'window-of-opportunity' frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120501
Title: A phase I study of temsirolimus and metformin in advanced solid tumours.
Journal: Investigational new drugs 20120401
Title: [Renal tolerance of targeted therapies].
Journal: Bulletin du cancer 20120301
Title: mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma.
Journal: Current treatment options in oncology 20120301
Title: Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.
Journal: Clinical obstetrics and gynecology 20120301
Title: Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
Journal: Cell death & disease 20120301
Title: Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120215
Title: Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120215
Title: Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210
Title: [PI3K-AKT-mTOR pathway and cancer].
Journal: Bulletin du cancer 20120201
Title: mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.
Journal: Endocrine-related cancer 20120201
Title: The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
Journal: European journal of cancer (Oxford, England : 1990) 20120201
Title: Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Journal: Journal of the National Cancer Institute 20120118
Title: mTOR pathway inhibition in renal cell carcinoma.
Journal: Urologic oncology 20120101
Title: An update on targeted therapy in metastatic renal cell carcinoma.
Journal: Urologic oncology 20120101
Title: The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Journal: Breast cancer research and treatment 20120101
Title: Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120101
Title: Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
Journal: Acta oncologica (Stockholm, Sweden) 20120101
Title: Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Journal: European journal of cancer (Oxford, England : 1990) 20120101
Title: Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).
Journal: British journal of haematology 20120101
Title: An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.
Journal: Journal of biopharmaceutical statistics 20120101
Title: Targeting mTOR pathways in human malignancies.
Journal: Current pharmaceutical design 20120101
Title: Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
Journal: Dermatology (Basel, Switzerland) 20120101
Title: Reactivation of tuberculosis during temsirolimus therapy.
Journal: Investigational new drugs 20111201
Title: Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors.
Journal: Cancer letters 20111201
Title: Inhibition of induced autophagy increases apoptosis of Nara-H cells.
Journal: International journal of oncology 20111201
Title: The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma.
Journal: Expert opinion on drug metabolism & toxicology 20111201
Title: [Antihormonal therapy in breast cancer and mTOR inhibitors].
Journal: Bulletin du cancer 20111201
Title: Hydrogel containing L-valine residues as a platform for cisplatin chemotherapy.
Journal: Colloids and surfaces. B, Biointerfaces 20111101
Title: Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Journal: The Journal of pharmacology and experimental therapeutics 20111101
Title: A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111101
Title: Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice.
Journal: Pain 20111101
Title: Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.
Journal: International journal of clinical oncology 20111001
Title: Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
Journal: Anti-cancer drugs 20111001
Title: Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Journal: Gynecologic oncology 20111001
Title: Erythematous patches and plaques on the chest with induration of the breasts. Metastatic papillary RCC in dermal lymphatics.
Journal: Archives of dermatology 20111001
Title: Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110915
Title: Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110910
Title: [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Journal: Der Urologe. Ausg. A 20110901
Title: Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
Journal: Acta dermato-venereologica 20110901
Title: Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110901
Title: Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.
Journal: Pathology international 20110901
Title: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820
Title: A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).
Journal: Cancer 20110801
Title: The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice.
Journal: The American journal of pathology 20110801
Title: mTOR inhibitors in advanced renal cell carcinoma.
Journal: Hematology/oncology clinics of North America 20110801
Title: [Adverse effects of new oncologic therapies].
Journal: Praxis 20110727
Title: Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110720
Title: CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.
Journal: Cancer research 20110715
Title: Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701
Title: Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
Journal: Cancer science 20110701
Title: Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Journal: The Lancet. Oncology 20110701
Title: Combination therapy in metastatic renal cell carcinoma.
Journal: The Lancet. Oncology 20110701
Title: [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Journal: Aktuelle Urologie 20110701
Title: Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
Journal: Anti-cancer drugs 20110601
Title: [Collecting duct renal cell carcinoma].
Journal: Actas urologicas espanolas 20110601
Title: Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Journal: Clinical and experimental nephrology 20110601
Title: Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features.
Journal: Journal of the American Academy of Dermatology 20110601
Title: Common toxicities of mammalian target of rapamycin inhibitors.
Journal: Targeted oncology 20110601
Title: Temsirolimus in relapsed and/or refractory mantle cell lymphoma†: profile report.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110601
Title: Everolimus- and temsirolimus-associated enteritis: report of three cases.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110510
Title: Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110501
Title: The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Journal: Oral oncology 20110501
Title: Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110501
Title: Efficacy and comparative effectiveness of sirolimus as an anticancer drug.
Journal: The Laryngoscope 20110501
Title: Isolation and structure of homotemsirolimuses A, B, and C.
Journal: Journal of natural products 20110425
Title: [Novelties in the treatment for advanced renal-cell cancer].
Journal: Orvosi hetilap 20110424
Title: Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110420
Title: Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Journal: Experimental hematology 20110401
Title: The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.
Journal: The Journal of clinical endocrinology and metabolism 20110401
Title: Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.
Journal: The Lancet. Oncology 20110401
Title: New combinations for mantle cell lymphoma: concerted action needed.
Journal: The Lancet. Oncology 20110401
Title: [Treatment of metastatic renal cell carcinoma].
Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110401
Title: mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
Journal: Oncology reports 20110301
Title: Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Journal: The Lancet. Oncology 20110301
Title: Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
Journal: Targeted oncology 20110301
Title: [Current status in molecular-targeted therapy and IFNα for renal cell carcinoma in Japan].
Journal: Hinyokika kiyo. Acta urologica Japonica 20110301
Title: Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
Journal: British journal of cancer 20110215
Title: Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110201
Title: Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Journal: The oncologist 20110201
Title: Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Journal: The oncologist 20110201
Title: Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Journal: The oncologist 20110201
Title: Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.
Journal: Annals of hematology 20110101
Title: Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110101
Title: Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response.
Journal: Urologia internationalis 20110101
Title: Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
Journal: PloS one 20110101
Title: Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Journal: Anticancer research 20110101
Title: Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
Journal: Journal of medical economics 20110101
Title: [Breast cancer therapy with combination of endocrine and target drugs].
Journal: Voprosy onkologii 20110101
Title: Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Journal: Oncology 20110101
Title: Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
Journal: Dermatology (Basel, Switzerland) 20110101
Title: A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
Journal: PloS one 20110101
Title: S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Journal: PloS one 20110101
Title: Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.
Journal: Blood 20101223
Title: Temsirolimus for metastatic desmoplastic small round cell tumor.
Journal: Pediatric blood & cancer 20101215
Title: Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20101215
Title: BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Journal: International journal of cancer 20101215
Title: Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
Journal: Head & neck 20101201
Title: Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat.
Journal: The journal of pain : official journal of the American Pain Society 20101201
Title: Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Journal: European urology 20101201
Title: mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Journal: Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20101201
Title: More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Journal: Anticancer research 20101201
Title: Temsirolimus and mantle cell lymphoma. Highly toxic, limited efficacy.
Journal: Prescrire international 20101201
Title: Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20101115
Title: Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL).
Journal: American journal of hematology 20101101
Title: Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101
Title: Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction.
Journal: Molecular cancer therapeutics 20101101
Title: Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Journal: Expert opinion on biological therapy 20101101
Title: The therapy of kidney cancer with biomolecular drugs.
Journal: Cancer treatment reviews 20101101
Title: Descending serotonergic facilitation mediated by spinal 5-HT3 receptors engages spinal rapamycin-sensitive pathways in the rat.
Journal: Neuroscience letters 20101029
Title: Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.
Journal: Drugs 20101001
Title: Combination therapy in patients with metastatic renal cell carcinoma.
Journal: Clinical advances in hematology & oncology : H&O 20101001
Title: Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Journal: Medical oncology (Northwood, London, England) 20100901
Title: Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer.
Journal: Journal of molecular medicine (Berlin, Germany) 20100901
Title: Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820
Title: Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
Journal: European urology 20100801
Title: A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Journal: Japanese journal of clinical oncology 20100801
Title: [Current impact of natural products in the discovery of anticancer drugs].
Journal: Annales pharmaceutiques francaises 20100701
Title: Temsirolimus: is improved survival the correct expression of drug activity?
Journal: The oncologist 20100701
Title: Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.
Journal: Medical oncology (Northwood, London, England) 20100601
Title: Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Journal: Investigational new drugs 20100601
Title: A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
Journal: Gynecologic oncology 20100601
Title: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
Journal: Anti-cancer drugs 20100601
Title: Treatment of metastatic renal cell carcinoma.
Journal: Nature reviews. Urology 20100601
Title: [mTOR inhibitors].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20100601
Title: Smooth muscle cells orchestrate the endothelial cell response to flow and injury.
Journal: Circulation 20100525
Title: Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.
Journal: British journal of cancer 20100511
Title: Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20100501
Title: Natural products in structure-assisted design of molecular cancer therapeutics.
Journal: Current pharmaceutical design 20100501
Title: Papillary renal cell carcinoma with cutaneous metastases.
Journal: The American journal of the medical sciences 20100501
Title: Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
Journal: Annals of neurology 20100501
Title: [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Journal: Aktuelle Urologie 20100501
Title: FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
Journal: The oncologist 20100401
Title: Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Journal: Journal of chemotherapy (Florence, Italy) 20100401
Title: [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Journal: Aktuelle Urologie 20100301
Title: Sirolimus and temsirolimus for epithelioid angiomyolipoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210
Title: Broadening the therapeutic scope for rapamycin treatment.
Journal: Autophagy 20100201
Title: [Treatment of locally advanced renal tumors].
Journal: Actas urologicas espanolas 20100201
Title: Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Journal: Cancer research 20100115
Title: Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101
Title: Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20100101
Title: Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20100101
Title: Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.
Journal: Brain : a journal of neurology 20100101
Title: Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Journal: Health technology assessment (Winchester, England) 20100101
Title: Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100101
Title: Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.
Journal: Cancer research 20100101
Title: Temsirolimus.
Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101
Title: Progress in the management of advanced renal cell carcinoma (RCC).
Journal: Aktuelle Urologie 20100101
Title: [First-line therapy of metastatic renal cell carcinoma--update 2009].
Journal: Onkologie 20100101
Title: [Outlook: Future therapy of renal cell carcinoma].
Journal: Onkologie 20100101
Title: New therapeutic strategies for renal cell carcinoma.
Journal: Urologic nursing 20100101
Title: [Renal cell carcinoma management and therapies in 2010].
Journal: Bulletin du cancer 20100101
Title: [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Journal: Bulletin du cancer 20100101
Title: [Targeted therapies: sequential and combined treatments].
Journal: Bulletin du cancer 20100101
Title: [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Journal: Bulletin du cancer 20100101
Title: [Advanced renal carcinomas with special situations. How to treat them?].
Journal: Bulletin du cancer 20100101
Title: Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.
Journal: PharmacoEconomics 20100101
Title: Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Journal: BMC cancer 20100101
Title: Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
Journal: Journal of hematology & oncology 20100101
Title: The DTH effector response and IL-2 are unaffected by cyclosporine A in autoimmune B6D2F1 mice.
Journal: Cellular immunology 20100101
Title: Targeted therapy in lymphoma.
Journal: Journal of hematology & oncology 20100101
Title: Perspectives in the development of novel treatment approaches.
Journal: Tumori 20100101
Title: Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Journal: Cancer treatment reviews 20091201
Title: Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Journal: Leukemia & lymphoma 20091201
Title: Metastatic renal cell carcinoma: current standards of care.
Journal: Clinical journal of oncology nursing 20091201
Title: Management of mTOR inhibitor side effects.
Journal: Clinical journal of oncology nursing 20091201
Title: Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies.
Journal: Seminars in oncology 20091201
Title: Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
Journal: Seminars in oncology 20091201
Title: Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Journal: Seminars in oncology 20091201
Title: Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Journal: Seminars in oncology 20091201
Title: Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
Journal: Seminars in oncology 20091201
Title: Temsirolimus for the treatment of mantle cell lymphoma.
Journal: Expert review of hematology 20091201
Title: Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
Journal: Leukemia research 20091101
Title: Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain)) 20091101
Title: Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
Journal: Journal of dermatological science 20091101
Title: [Antitumoral effect of proliferation signal inhibitors].
Journal: Gastroenterologie clinique et biologique 20091101
Title: Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.
Journal: Current hematologic malignancy reports 20091001
Title: Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
Journal: Cancer research 20090915
Title: Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090915
Title: Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Journal: Current opinion in supportive and palliative care 20090901
Title: Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090901
Title: [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901
Title: Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Journal: Cancer 20090815
Title: Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Journal: Cancer 20090815
Title: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810
Title: Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
Journal: Molecular cancer therapeutics 20090801
Title: Eosinophilic rash secondary to temsirolimus.
Journal: Clinical genitourinary cancer 20090801
Title: Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Journal: Clinical therapeutics 20090801
Title: Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
Journal: Cancer chemotherapy and pharmacology 20090701
Title: Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
Journal: BJU international 20090701
Title: (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090701
Title: [The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line].
Journal: Zhonghua nan ke xue = National journal of andrology 20090701
Title: [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601
Title: Inhibition of IGF-I receptor signaling in combination with rapamycin or temsirolimus increases MYC-N phosphorylation.
Journal: Anticancer research 20090601
Title: The role of antiangiogenesis therapy: bevacizumab and beyond.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090601
Title: Targeting mTOR in renal cell carcinoma.
Journal: Cancer 20090515
Title: Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
Journal: Cancer chemotherapy and pharmacology 20090501
Title: Ready for a comeback of natural products in oncology.
Journal: Biochemical pharmacology 20090501
Title: Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Journal: Cancer treatment reviews 20090501
Title: Tolerability of first-line therapy for metastatic renal cell carcinoma.
Journal: Cancer treatment reviews 20090501
Title: Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Journal: International journal of urology : official journal of the Japanese Urological Association 20090501
Title: [Targeted therapies and their indications in solid neoplasias].
Journal: La Revue de medecine interne 20090501
Title: Targeted therapies in metastatic renal cancer in 2009.
Journal: BJU international 20090501
Title: Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Journal: The oncologist 20090501
Title: The applicability of mTOR inhibition in solid tumors.
Journal: Current cancer drug targets 20090501
Title: The pharmacology of mTOR inhibition.
Journal: Science signaling 20090421
Title: Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.
Journal: Clinical journal of oncology nursing 20090401
Title: Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Journal: Cancer chemotherapy and pharmacology 20090301
Title: Recent advances in the systemic treatment of metastatic papillary renal cancer.
Journal: Expert review of anticancer therapy 20090301
Title: AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
Title: Temsirolimus in patients with advanced renal cell carcinoma: an overview.
Journal: Advances in therapy 20090101
Title: Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Journal: BMC cancer 20090101
Title: [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Journal: Aktuelle Urologie 20090101
Title: [Topics in mTOR pathway and its inhibitors].
Journal: Bulletin du cancer 20090101
Title: Temsirolimus-induced glomerulopathy.
Journal: Oncology 20090101
Title: Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.
Journal: Clinical genitourinary cancer 20090101
Title: Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Journal: Medical oncology (Northwood, London, England) 20090101
Title: New therapeutic approaches in the management of metastatic renal cell carcinoma.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090101
Title: [Acute renal failure in a patient with renal carcinoma treated with temsirolimus].
Journal: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101
Title: Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.
Journal: Breast cancer research : BCR 20090101
Title: Exploring the role of novel agents in the treatment of renal cell carcinoma.
Journal: Cancer treatment reviews 20081201
Title: Temsirolimus in patients with renal cancer on hemodialysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201
Title: Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Journal: Cancer biology & therapy 20081201
Title: Temsirolimus in renal cell carcinoma.
Journal: Transplantation proceedings 20081201
Title: Temsirolimus: new drug. Metastatic kidney cancer: more assessment needed.
Journal: Prescrire international 20081201
Title: [Molecular basis of targeted therapy in metastatic renal cancer].
Journal: Der Pathologe 20081101
Title: Mechanism of action of rapalogues: the antiangiogenic hypothesis.
Journal: Expert opinion on investigational drugs 20081101
Title: Systemic therapy for metastatic renal cell carcinoma.
Journal: The Urologic clinics of North America 20081101
Title: mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
Journal: British journal of cancer 20081021
Title: [Value of targeted therapies for renal cell cancer].
Journal: Der Urologe. Ausg. A 20081001
Title: Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Journal: Nature clinical practice. Oncology 20081001
Title: Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain)) 20081001
Title: [Targeted therapy - point blank or single shot].
Journal: Der Urologe. Ausg. A 20081001
Title: Novel drugs for renal cell carcinoma.
Journal: Expert opinion on investigational drugs 20081001
Title: [Systemic therapy of metastasizing renal cell carcinoma].
Journal: Der Urologe. Ausg. A 20081001
Title: Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Journal: European journal of cancer (Oxford, England : 1990) 20081001
Title: [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001
Title: Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Journal: The oncologist 20081001
Title: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.
Journal: European journal of pharmacology 20080904
Title: Targeted therapy in renal cell carcinoma.
Journal: Current opinion in urology 20080901
Title: Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.
Journal: Reviews on recent clinical trials 20080901
Title: [Renal cell carcinoma].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20080901
Title: NCCN Task Force Report: mTOR inhibition in solid tumors.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20080901
Title: Watchdog set to reject four drugs for kidney cancer on the NHS.
Journal: BMJ (Clinical research ed.) 20080814
Title: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080801
Title: Temsirolimus in metastatic renal cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080801
Title: Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
Journal: Cancer 20080801
Title: Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Journal: Clinical journal of oncology nursing 20080801
Title: Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.
Journal: Journal of hepatology 20080701
Title: New drugs08, part 2.
Journal: Nursing 20080701
Title: Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Journal: Oncology nursing forum 20080701
Title: Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.
Journal: British journal of cancer 20080603
Title: Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.
Journal: Molecular cancer therapeutics 20080601
Title: [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20080601
Title: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Journal: European urology 20080501
Title: Renal cell carcinoma.
Journal: Current opinion in oncology 20080501
Title: Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20080501
Title: A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Journal: Cancer research 20080415
Title: [Renal cell carcinoma and antiangiogenic therapies].
Journal: Presse medicale (Paris, France : 1983) 20080401
Title: Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Journal: Experimental hematology 20080401
Title: Treatment options for metastatic renal cell carcinoma: a review.
Journal: The Canadian journal of urology 20080401
Title: Drug essentials mTOR inhibitors.
Journal: Oncology (Williston Park, N.Y.) 20080401
Title: Temsirolimus, an inhibitor of mammalian target of rapamycin.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080301
Title: [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
Journal: Nederlands tijdschrift voor geneeskunde 20080216
Title: Pulmonary complications of novel antineoplastic agents for solid tumors.
Journal: Chest 20080201
Title: The potential role of mTOR inhibitors in non-small cell lung cancer.
Journal: The oncologist 20080201
Title: [Molecular targeted therapy for renal cell carcinoma].
Journal: Hinyokika kiyo. Acta urologica Japonica 20080101
Title: Pathobiology and prognosis of chromophobe renal cell carcinoma.
Journal: Urologic oncology 20080101
Title: Temsirolimus: in advanced renal cell carcinoma.
Journal: Drugs 20080101
Title: An update on the medical therapy of advanced metastatic renal cell carcinoma.
Journal: Scandinavian journal of urology and nephrology 20080101
Title: IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth.
Journal: Anticancer research 20080101
Title: Signaling inhibitors in metastatic renal cell carcinoma.
Journal: Cancer journal (Sudbury, Mass.) 20080101
Title: Targeted drugs for metastatic renal cell carcinoma.
Journal: Lancet (London, England) 20071222
Title: Temsirolimus (Torisel) for advanced renal cell carcinoma.
Journal: The Medical letter on drugs and therapeutics 20071217
Title: Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20071215
Title: [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Journal: Ai zheng = Aizheng = Chinese journal of cancer 20071201
Title: Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications.
Journal: Journal of clinical pharmacology 20071101
Title: A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071101
Title: Temsirolimus for advanced renal cell carcinoma.
Journal: Clinical advances in hematology & oncology : H&O 20071101
Title: Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Journal: The Journal of investigative dermatology 20071001
Title: Rapamycin: something old, something new, sometimes borrowed and now renewed.
Journal: Clinical pharmacology and therapeutics 20071001
Title: Temsirolimus.
Journal: Drugs of today (Barcelona, Spain : 1998) 20071001
Title: Temsirolimus for advanced renal-cell carcinoma.
Journal: The New England journal of medicine 20070906
Title: Temsirolimus for advanced renal-cell carcinoma.
Journal: The New England journal of medicine 20070906
Title: In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20070901
Title: Treatment options in renal cell carcinoma: past, present and future.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070901
Title: Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901
Title: Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901
Title: Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Journal: Clinical genitourinary cancer 20070901
Title: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Journal: Clinical genitourinary cancer 20070901
Title: American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Journal: IDrugs : the investigational drugs journal 20070801
Title: The biology behind mTOR inhibition in sarcoma.
Journal: The oncologist 20070801
Title: Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
Journal: Expert review of anticancer therapy 20070801
Title: The role of mTOR inhibitors for treatment of sarcomas.
Journal: Current oncology reports 20070701
Title: Temsirolimus in the treatment of advanced renal cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070701
Title: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Journal: The New England journal of medicine 20070531
Title: Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
Journal: Onkologie 20070501
Title: Clinical development of mTOR inhibitors: a focus on lymphoma.
Journal: Reviews on recent clinical trials 20070501
Title: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
Journal: Blood 20070415
Title: AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
Journal: Oncogene 20070405
Title: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
Journal: British journal of cancer 20070326
Title: Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
Journal: Cancer research 20070301
Title: Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
Journal: Cancer treatment reviews 20070201
Title: Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.
Journal: Molecular cancer therapeutics 20070201
Title: Evaluating the activity of temsirolimus in neuroendocrine cancer.
Journal: British journal of cancer 20070115
Title: New therapeutics for soft-tissue sarcomas in adults.
Journal: Oncology (Williston Park, N.Y.) 20070101
Title: Newly approved therapies for RCC and their effect on the standard of care.
Journal: Clinical advances in hematology & oncology : H&O 20070101
Title: CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.
Journal: Pharmacology 20070101
Title: Advanced renal cell carcinoma: current and emerging management strategies.
Journal: Drugs 20070101
Title: The role of targeted therapy in metastatic renal cell carcinoma.
Journal: TheScientificWorldJournal 20070101
Title: [Effect of angiogenesis inhibitors on renal cell carcinoma].
Journal: Magyar onkologia 20070101
Title: New drugs: ambrisentan, temsirolimus, and eculizumab.
Journal: Journal of the American Pharmacists Association : JAPhA 20070101
Title: Molecule of the month. Temsirolimus.
Journal: Drug news & perspectives 20070101
Title: [Angiogenesis targeting in renal carcinomas].
Journal: Bulletin du cancer 20070101
Title: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
Journal: BMC pharmacology 20070101
Title: Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20061215
Title: Targeted therapy for metastatic renal cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061210
Title: Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Journal: Expert review of anticancer therapy 20061201
Title: Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Journal: Expert review of anticancer therapy 20061201
Title: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.
Journal: British journal of cancer 20061106
Title: [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Journal: Bulletin du cancer 20061101
Title: Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
Journal: Genes, chromosomes & cancer 20061001
Title: A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20061001
Title: Molecular biology of renal cell carcinoma.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061001
Title: Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
Journal: Clinical breast cancer 20061001
Title: Three new drugs available to fight kidney cancer.
Journal: Journal of the National Cancer Institute 20060906
Title: New treatment approaches in metastatic renal cell carcinoma.
Journal: Current opinion in urology 20060901
Title: Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus.
Journal: Endocrine-related cancer 20060901
Title: Therapeutic targets: MTOR and related pathways.
Journal: Cancer biology & therapy 20060901
Title: Current status of clinical trials for glioblastoma.
Journal: Reviews on recent clinical trials 20060901
Title: Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.
Journal: European journal of cancer (Oxford, England : 1990) 20060801
Title: An in vivo platform for translational drug development in pancreatic cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060801
Title: New hope for RCC patients.
Journal: European journal of cancer (Oxford, England : 1990) 20060801
Title: Trials probe new agents for kidney cancer.
Journal: JAMA 20060712
Title: Mammalian target of rapamycin inhibitors in sarcomas.
Journal: Current opinion in oncology 20060701
Title: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Journal: Anti-cancer drugs 20060601
Title: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Journal: Cancer research 20060601
Title: Perspectives in central nervous system malignancies.
Journal: IDrugs : the investigational drugs journal 20060601
Title: Targeting mTOR for cancer treatment.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060601
Title: New therapies in the treatment of breast cancer.
Journal: Seminars in oncology 20060601
Title: Molecular targeting therapy for renal cell carcinoma.
Journal: International journal of clinical oncology 20060601
Title: In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Journal: International journal of cancer 20060501
Title: Autophagy: A protective mechanism in response to stress and inflammation.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060501
Title: CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.
Journal: Neoplasia (New York, N.Y.) 20060501
Title: Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Journal: Cancer research 20060215
Title: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.
Journal: Blood 20060201
Title: mTOR and cancer: reason for dancing at the crossroads?
Journal: Current opinion in genetics & development 20060201
Title: [Progress in therapeutic strategy for renal cell carcinoma].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20060201
Title: mTOR inhibitors.
Journal: Clinical advances in hematology & oncology : H&O 20060101
Title: Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20060101
Title: PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2.
Journal: Biochemical and biophysical research communications 20051104
Title: Mammalian target of rapamycin as a therapeutic target in leukemia.
Journal: Current molecular medicine 20051101
Title: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Journal: Molecular cancer therapeutics 20051001
Title: Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy.
Journal: Clinical breast cancer 20051001
Title: CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
Journal: Cancer 20050901
Title: lipase-catalyzed regioselective esterification of rapamycin: synthesis of temsirolimus (CCI-779).
Journal: Organic letters 20050901
Title: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810
Title: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810
Title: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810
Title: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
Journal: Investigational new drugs 20050801
Title: Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition.
Journal: Hepatology (Baltimore, Md.) 20050601
Title: [Experimental study of Mytrolimus-eluting stents on preventing restenosis in porcine coronary model].
Journal: Zhonghua xin xue guan bing za zhi 20050601
Title: The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.
Journal: Biochemical and biophysical research communications 20050527
Title: Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Journal: Cancer research 20050415
Title: Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Journal: Cancer research 20050401
Title: mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
Journal: Neoplasia (New York, N.Y.) 20050401
Title: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.
Journal: Cancer research 20050315
Title: Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Journal: Genes, chromosomes & cancer 20050301
Title: Scientists hopeful as they uncover molecular clues to prostate cancer.
Journal: Journal of the National Cancer Institute 20050202
Title: Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050201
Title: Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.
Journal: Clinical pharmacology and therapeutics 20050101
Title: Inhibition of different intracellular signal cascades in human pancreatic cancer cells.
Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20050101
Title: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.
Journal: Molecular cancer 20050101
Title: In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.
Journal: Blood 20041215
Title: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20041201
Title: [16th EORTC-NCI-AACR symposium on new molecular targets and cancer therapeutics].
Journal: Bulletin du cancer 20041201
Title: Mammalian target of rapamycin.
Journal: Seminars in oncology 20041201
Title: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
Journal: Investigational new drugs 20041101
Title: Combining targeted agents in lung cancer.
Journal: Clinical lung cancer 20041101
Title: New target, new drug, old paradigm.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040615
Title: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040615
Title: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301
Title: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Journal: Cancer 20040215
Title: Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor.
Journal: The Journal of urology 20040201
Title: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.
Journal: The Journal of biological chemistry 20040123
Title: Overcoming endocrine therapy resistance by signal transduction inhibition.
Journal: The oncologist 20040101
Title: New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Journal: Breast cancer research : BCR 20040101
Title: Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779.
Journal: Drugs in R&D 20040101
Title: New therapeutic strategies for soft tissue sarcomas.
Journal: Current treatment options in oncology 20031201
Title: Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030801
Title: Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030801
Title: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20030601
Title: Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth.
Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20030101
Title: Synthetic lethality: killing cancer with cancer.
Journal: Journal of the National Cancer Institute 20021120
Title: Clinical development of mammalian target of rapamycin inhibitors.
Journal: Hematology/oncology clinics of North America 20021001
Title: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Journal: Cancer research 20020901
Title: Goosebumps.
Journal: Lancet (London, England) 20020831
Title: CCI-779 Wyeth.
Journal: Current opinion in investigational drugs (London, England : 2000) 20020801
Title: Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Journal: Current opinion in investigational drugs (London, England : 2000) 20020201
Title: Rapamycin's resurrection: a new way to target the cancer cell cycle.
Journal: Journal of the National Cancer Institute 20011017
Title: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
Journal: Endocrine-related cancer 20010901
Title: Advances in systemic therapy of small cell cancer of the lung.
Journal: Expert review of anticancer therapy 20010801
Title: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20010601
Title: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Journal: Cancer research 20010215
Title: Shor B, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res, 2008, 68(8), 2934-2943.
Title: Wu L, et al. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res, 2005, 65(7), 2825-2831.
Title: Teachey DT, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood, 2006, 107(3), 1149-1155.
Title: Geoerger B, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res, 2001, 61(4), 1527-1532.
Title: Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004 Jun;36(6):585-95. Epub 2004 May 16.
Title: Frost P, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004 Dec 15;104(13):4181-7. Epub 2004 Aug 10.
Title: Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116.
Title: Jason C. Choi, et al. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci Transl Med. 2012 Jul 25; 4(144): 144ra102.
